Ivonescimab for recurrent glioblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called ivonescimab for people whose glioblastoma has come back after standard treatment. The goal is to see if this drug can help shrink the tumor or slow its growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your glioblastoma has come back after at least one standard treatment (radiation with or without chemotherapy).
- You are able to take care of yourself (Karnofsky score of 60 or higher).
- You have not had prior treatment with certain other drugs like Avastin or Keytruda.
- Your organs (kidneys, liver, bone marrow) are working well enough based on blood tests.
- You are not taking more than 2 mg of dexamethasone (a steroid) per day.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—trimipramine (an antidepressant), atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy)—in people whose glioblastoma has come back after initial treatment. The goal is to see if this mix can help shrink the tumor or slow its growth.
This trial studies different treatment regimens for people with glioblastoma that is either newly diagnosed or has come back. It aims to find which treatment approach works best for controlling the tumor and improving outcomes.
This trial tests a new injection called VRT106 for people whose glioblastoma (a brain tumor) has come back or is growing. It uses a virus that may help the immune system attack the tumor. This study is for those who have not had a similar virus or gene therapy before.
This study tests a new drug called ivonescimab for people with advanced adrenal gland tumors (adrenocortical carcinoma or pheochromocytoma/paraganglioma) that cannot be removed with surgery. The goal is to see if the drug can reduce or stop the growth of the tumors.
This trial combines two immunotherapy drugs (ipilimumab and nivolumab) given through a vein and directly into the brain for people with recurrent glioblastoma. The goal is to see if this approach can help control the tumor.
This trial tests a combination of two drugs—ivoximab (a new immunotherapy) and temozolomide (chemotherapy)—to treat gliomas (brain tumors) that have come back or stopped responding to prior treatment. The goal is to see if this combination is safe and effective.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.